Drug Development

After a blockbuster IPO raised nearly $300 million, dermatologist-founded Veradermics is poised to challenge the hair loss market with its new oral pill.

iVeena promotes key execs as it prepares for clinical trials of a novel eye drop that could reshape pediatric myopia treatment worldwide.

A simple nasal spray could offer immediate, broad protection against the flu. New landmark studies show how this antibody-based shield could revolutionize prevention.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

Current blood thinners carry a risky trade-off. A new class of drugs targeting Factor XIa could prevent deadly clots without the dangerous bleeding.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

The market for drugs like Ozempic and Wegovy is set to explode, fueled by new oral pills, expanded uses for heart and liver disease, and fierce competition.

A new grant funds a radical approach using AI and postmortem human brains to find crucial clues for Parkinson's therapies, aiming to crack a major medical challenge.

A French biotech is advancing a novel class of drugs that don't just fight cravings but may reverse the deep-seated brain changes caused by addiction.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

A new strategic partnership aims to dismantle commercialization hurdles, promising faster access to life-saving therapies for rare disease patients.

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

BioAge Labs is developing an oral drug for diabetic macular edema, a breakthrough that could end the need for frequent, invasive eye injections for millions.

Ascletis Pharma unveils ASC37, a next-gen, once-monthly obesity drug claiming superior potency and convenience, challenging giants like Eli Lilly.

Corvus Pharmaceuticals is set to unveil pivotal early data for its novel eczema drug, soquelitinib, a moment analysts call a critical milestone.

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.